Company Antibe Therapeutics Inc Toronto S.E.
Equities
ATE
CA0370251039
Biotechnology & Medical Research
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Alain Wilson
DFI | Director of Finance/CFO | - | 15-11-30 |
Chief Tech/Sci/R&D Officer | - | - | |
Ana Stegic
CTO | Chief Tech/Sci/R&D Officer | - | - |
Scott Curtis
COO | Chief Operating Officer | - | 15-12-31 |
Joseph Stauffer
CTO | Chief Tech/Sci/R&D Officer | 58 | 20-05-05 |
Investor Relations Contact | - | - | |
David Vaughan
PRN | Corporate Officer/Principal | 74 | 12-10-31 |
Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 50 | 20-11-23 | |
Amal Khouri
BRD | Director/Board Member | - | 18-03-18 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 53,009,362 | 48,481,043 ( 91.46 %) | 0 | 91.46 % |
Company contact information
Antibe Therapeutics, Inc.
15 Prince Arthur Avenue
M5R 1B2, Toronto
+416-922-3460
http://www.antibethera.com![address Antibe Therapeutics Inc(ATE)](https://cdn.zonebourse.com/static/address/13421489.png)
Sector
1st Jan change | Capi. | |
---|---|---|
+20.82% | 127B | |
+21.96% | 116B | |
+23.87% | 27.69B | |
-22.97% | 19.62B | |
-16.91% | 16.26B | |
-19.03% | 15.49B | |
+11.66% | 14.81B | |
-48.41% | 14.39B | |
+54.78% | 14.11B |